A muscarinic antagonist for the treatment of overactive bladder with urge urinary incontinence, urgency and freuency.
Decreases urge urinary incontinence at week 12 by a median reduction of 88% versus 50% with placebo at a 8 mg dose.
May be associated with angioedema of the face, lips, tongue and lower larynx.
Should be used with caution in patients with significant bladder outlet obstruction, decreased gastrointestinal motility, controlled narrow angle glaucoma or myasthenia gravis.
Most frequent adverse events dry mouth, and constipation.
Dose 4 mg/day and may be increased to 8 mg once daily.